Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Third article in Paolo's Biotech Notes series. PDF attached and uploaded. Additionally, Paolo has provided a relevant timely article. ContraFect Corp (CFRX) has a promising pipeline with a potential ...
Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results